ABSTRACT

Background: Dengue fever is one of the most common mosquito-borne viral illnesses in the world. It is usually transmitted to humans through the bite of an infected Aedes aegypti or Aedes albopictus mosquito. Dengue infections are caused by four antigenically distinct but closely related viruses (DEN 1–4). Infection with any one of the viruses is thought to provide lifetime immunity to future infections from the same virus but only short-term cross-immunity to the other types, leading to the possibility of secondary infections. Dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS), more severe types of dengue infections, sometimes result when an individual is subsequently infected with a second virus serotype during their lifetime. The most commonly accepted theory for the development of these more severe dengue infections is that of antibody-dependent enhancement, although other factors likely play a role. Infections complicated by DHF/DSS in areas where dengue is endemic are most often seen in the later half of the first year of life, when waning maternal antibodies may enhance the development of a more severe infection, and in young school-age children experiencing secondary infections. Widespread infections are most commonly seen during the rainy season of endemic areas when the breeding habitat of the Aedes mosquito is most favorable.

Keywords: dengue hemorrhagic fever, dengue shock syndrome, mosquito-borne viral illness

Clinical

Dengue infections with any one of the four serotypes can cause a wide range of illness. Those infected will usually be asymptomatic or have a nonspecific febrile illness. Less than half of those infected will manifest as classic dengue fever or severe dengue infections (dengue hemorrhagic fever/dengue shock syndrome [DHF/DSS]).

In recent years, some changes were made in the nomenclature regarding dengue infections, but the clinical manifestations of the disease remains the same. Symptomatic dengue infections are characterized by fever, lasting between 2–7 days, accompanied by retro-orbital pain and intense muscle and joint discomfort. (Dengue is also known as breakbone fever.)

Petechiae can present early in the course of the illness or may be seen following a tourniquet test. This test is conducted by inflating a blood pressure cuff to a middle point between the patient’s systolic and diastolic blood pressures for 5 minutes and then counting the number of petechiae present in a 1-inch² area—more than 20 is typically called a “positive” test. Recent studies have not shown this to be a particularly sensitive test, meaning that the lack of a “positive” test does not rule out a dengue infection.

In recent years, some changes were made in the nomenclature regarding dengue infections, but the clinical manifestations of the disease remains the same. Symptomatic dengue infections are characterized by fever, lasting between 2–7 days, accompanied by retro-orbital pain and intense muscle and joint discomfort. (Dengue is also known as breakbone fever.)

Petechiae can present early in the course of the illness or may be seen following a tourniquet test. This test is conducted by inflating a blood pressure cuff to a middle point between the patient’s systolic and diastolic blood pressures for 5 minutes and then counting the number of petechiae present in a 1-inch² area—more than 20 is typically called a “positive” test. Recent studies have not shown this to be a particularly sensitive test, meaning that the lack of a “positive” test does not rule out a dengue infection.

Thrombocytopenia and leukopenia are often seen as well as an elevation of hepatic enzymes. Toward the end of the febrile period of the illness, a confluent rash may develop, which has been described as a “sea of red” sparing “islands” of the patient’s normal skin tone. Following resolution of the fever, adult patients often take weeks to recover physically and psychologically with profound fatigue and not uncommonly depressive symptoms while recovering from the illness.

A small percentage of adults and children go on to develop a more severe form of dengue, with signs and symptoms appearing at the time of defervescence. These severe dengue illnesses—DHF/DSS—are characterized by plasma leakage into the extravascular space. If not recognized early in the course of the illness, shock and death can result. It is impossible to predict which patients recovering from classic dengue fever will go on to develop more severe forms of the disease. Physicians experienced in endemic areas often report that patients who go on to more severe disease report abdominal pain out of proportion to their illness and feelings of “impending doom.” Secondary infections, with differing serotypes of dengue infections, have a higher risk.
of worsening to more severe types of dengue infections. These types of dengue infections should be managed with judicious boluses of isotonic crystalloid fluids to prevent irreversible shock.

**Editor’s Note:** The WHO Guide can be downloaded from http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf.

The most recent Centers for Disease Control and Prevention clinical descriptions for case definitions are as follows:

**Dengue fever** is most commonly an acute febrile illness defined by the presence of fever and two or more of the following: retro-orbital or ocular pain, headache, rash, myalgia, arthralgia, leukopenia, or hemorrhagic manifestations (e.g., positive tourniquet test, petechiae; purpura/ecchymosis; epistaxis; gum bleeding; blood in vomitus, urine, or stool; or vaginal bleeding) but not meeting the case definition of dengue hemorrhagic fever. Anorexia, nausea, abdominal pain, and persistent vomiting may also occur but are not case-defining criteria for dengue fever.

**Dengue hemorrhagic fever** is characterized by all of the following:

- Fever lasting 2–7 days
- Evidence of hemorrhagic manifestation or a positive tourniquet test
- Thrombocytopenia (≤ 100,000 cells/mm³)

Evidence of plasma leakage shown by hemoconcentration (an increase in hematocrit ≥ 20% above average for age or a decrease in hematocrit ≥ 20% of baseline following fluid replacement therapy), or pleural effusion, or ascites or hypoproteinemia.

**Dengue shock syndrome** has all of criteria for DHF plus circulatory failure as evidenced by:

- Rapid and weak pulse and narrow pulse pressure (> 20mm Hg) or
- Age-specific hypotension and cold, clammy skin and restlessness

**Diagnosis**

Dengue can be diagnosed within the first several days of the onset of fever by detection of a nonstructural component (NS-1) of the virus particle by reverse transcription-polymerase chain reaction or later by serologic testing for antidengue immunoglobulin M or G (IgM/IgG) by enzyme-linked immunosorbent assay (ELISA). The differential of dengue in the initial phase of the illness, before a definitive diagnosis can be made, should be broad and must include, among others, malaria, rickettsial infections, typhoid, and leptospirosis, as well as sepsis.

**Treatment**


**Vaccination**

No vaccination currently exists, although the U.S. Army and Navy are both actively involved in research in conjunction with laboratories around the world to develop one. Among the complexities in creating a dengue vaccine is that it must adequately cover all four dengue serotypes (DEN 1–4) to avoid severe infections in recipients who may be subsequently infected by serotypes not well protected by a combination vaccine.

**Importance in a Deployed Setting**

With no vaccine or chemoprophylaxis available, prevention of dengue infections through the use of bednets, mosquito control of billeting areas, the use of N,N-diethyl-meta-toluamide (DEET)-containing mosquito repellent, and permethrin pretreatment of uniforms is critically important while operating in the tropical areas of the world where dengue is endemic. Also important to understand is that the *Aedes* mosquito is a day biting mosquito, which thrives in urban environments where the risk of infection is greatest.

**Disclaimer**

The views expressed in this publication are those of the author and do not reflect the official policy or position of the Department of the Army, Department of Defense, or the Government.

**Bibliography**


(article continues on page 68)
DENGUE CASE

NEGATIVE

Co-existing conditions
Social circumstances

NEGATIVE

DENGUE WITHOUT WARNING SIGNS

Group A
(May be sent home)

Group criteria
Patients who do not have warning signs AND who are able:
- to tolerate adequate volumes of oral fluids
- to pass urine at least once every 6 hours

Laboratory tests
- full blood count (FBC)
- haematocrit (HCT)

Treatment
Advice for:
- adequate bed rest
- adequate fluid intake
- Paracetamol, 4 gram maximum per day in adults and accordingly in children.

Patients with stable HCT can be sent home.

Monitoring
Daily review for disease progression:
- decreasing white blood cell count
defervescence
- warning signs (until out of critical period)
Advice for immediate return to hospital if development of any warning signs, and written advice for management (e.g., home care card for dengue).

NEGATIVE

DENGUE WITH WARNING SIGNS

Group B
(Referred for in-hospital care)

Group criteria
Patients with any of the following features:
- co-existing conditions such as pregnancy, infancy, old age, diabetes mellitus, renal failure
- social circumstances such as living alone, living far from hospital

Laboratory tests
- full blood count (FBC)
- haematocrit (HCT)

Treatment
Encouragement for oral fluids. If not tolerated, start intravenous fluid therapy 0.9% saline or Ringer’s Lactate at maintenance rate.

Laboratory tests
- full blood count (FBC)
- haematocrit (HCT)

Treatment
- Obtain reference HCT before fluid therapy.
- Give isotonic solutions such as 0.9% saline, Ringer’s Lactate. Start with 3–4 ml/kg/hr for 1–2 hours, then reduce to 2–3 ml/kg/hr for 2–4 hr, and then reduce to 2–3 ml/kg/hr or less according to clinical response.

CR: Existing warning signs

Laboratory tests
- full blood count (FBC)
- haematocrit (HCT)

Treatment
- Reassess clinical status and repeat HCT.
- If HCT remains the same or rises only minimally > continue with 2–3 ml/kg/hr for another 2–4 hours;
- If worsening of vital signs and rapidly rising HCT > increase rate to 5–10 ml/kg/hr for 1–2 hours.

Reassess clinical status, repeat HCT and review fluid infusion rates accordingly:
- reduce intravenous fluids gradually when the rate of plasma leakage decreases towards the end of the critical phase.

This is indicated by:
- adequate urine output and/or fluid intake
- HCT decreases below the baseline value in a stable patient.

Monitoring
- vital signs and peripheral perfusion (1–4 hourly until patient is out of critical phase)
- urine output (4–6 hourly)
- HCT (before and after fluid replacement, then 6–12 hourly)
- blood glucose
- other organ function (renal profile, liver profile, coagulation profile, as indicated).
**MANAGEMENT**

**POSITIVE**

**SEVERE DENGUE**

**Group C**

(Require emergency treatment)

**Group criteria**
- Patients with any of the following features:
  - severe plasma leakage with shock and/or fluid accumulation with respiratory distress
  - severe bleeding
  - severe organ impairment

**Laboratory tests**
- full blood count (FBC)
- haematocrit (HCT)
- other organ function tests as indicated

**Treatment of compensated shock**
Start IV fluid resuscitation with isotonic crystalloid solutions at 5–10 ml/kg/hr over 1 hour. Reassess patients’ condition.

**If patient improves:**
- IV fluids should be reduced gradually to 5–7 ml/kg/hr for 1–2 hours, then to 3–5 ml/kg/hr for 2–4 hours, then to 2.3 ml/kg/hr for 2–4 hours and then reduced further depending on haemodynamic status;
- IV fluids can be maintained for up to 24–48 hours.

**If patient is still unstable:**
- check HCT after first bolus;
- if HCT increases/still high (>50%), repeat a second bolus of crystalloid solution at 10–20 ml/kg/hr for 1 hour;
- if there is improvement after second bolus, reduce rate to 7–10 ml/kg/hr for 1–2 hours and continue to reduce as above;
- if HCT decreases, this indicates bleeding and need to cross-match and transfuse blood as soon as possible.

**Treatment of hypotensive shock**
Initiate IV fluid resuscitation with crystalloid or colloid solution at 20 ml/kg as a bolus for 15 minutes.

**If patient improves:**
- give a crystalloid/colloid solution of 10 ml/kg/hr for 1 hour, then reduce gradually as above.

**If patient is still unstable:**
- review the HCT taken before the first bolus;
- if HCT was low (<40% in children and adult females, <45% in adult males) this indicates bleeding, the need to cross-match and transfuse (see above);
- if HCT was high compared to baseline value, change to IV colloids at 10–20 ml/kg as a second bolus over 30 minutes to 1 hour; reassess after second bolus.
- if patient is improving reduce the rate to 7–10 ml/kg/hr for 1–2 hours, then back to IV crystalloids and reduce rates as above;
- if patient’s condition is still unstable, repeat HCT after second bolus.
- if HCT decreases, this indicates bleeding (see above);
- if HCT increases/remains high (>50%), continue colloidal infusion at 10–20 ml/kg as a third bolus over 1 hour, then reduce to 7–10 ml/kg/hr 1–2 hours, then change back to crystalloid solution and reduce rate as above.

**Treatment of haemorrhagic complications**
Give 5–10 ml/kg of fresh packed red cells or 10–20 ml/kg of fresh whole blood.
Recommended Internet Links

http://www.cdc.gov/Dengue/
http://www.who.int/topics/dengue/en/

COL Burnett is the Chief of Pediatric Infectious Disease and Travel Medicine at Tripler Army Medical Center in Hawaii. A congenital Green Bay Packers fan, he has served overseas in Korea, Germany, Kosovo, Iraq, and Afghanistan and, most recently, as the JSOTF-P Surgeon in the Philippines. He is a graduate of the University of Wisconsin-Madison and the Medical College of Wisconsin. E-mail: mark.w.burnett.mil@mail.mil

Disclosure
The author has nothing to disclose.

EMS FELLOWSHIP OPPORTUNITIES

One or two year fellowships are available in EMS for emergency medicine residency-trained physicians. The programs provide training and education in all aspects of EMS including academics, administration, medical oversight, research, teaching and clinical components. The fellowship programs are tailored towards academic and operational EMS. The fellowship graduate will be prepared for a career in academic EMS and/or medical direction of a local or regional EMS system.

Yale University School of Medicine/EMS Fellowship
For more information:
David C. Cone, MD
Yale Emergency Medicine
Phone: 203-785-4710
Fax: 203-785-3196
e-mail: david.cone@yale.edu

Central Michigan University College of Medicine/EMS Fellowship
For more information contact:
Noel Wagner, MD, NREMT-P
EMS Fellowship Director
e-mail: noel.wagner@cmich.edu

Baylor College of Medicine/EMS Fellowship
For more information, contact:
Ira Nemeth, MD, FACEP
Director, Division of EMS and Disaster Medicine
e-mail: nemeth@bcm.edu

The Geisinger Health System/EMS Fellowship
For more information contact:
David J. Schoenwetter, DO, FACEP
e-mail: dj_schoenwetter@geisinger.edu
Phone: 570-457-3237

University of California San Francisco/EMS and Disaster Medicine Fellowship
For more information:
Website: http://emergency.ucsf.edu/fellowships
John F. Brown, MD MPA
EMS/Disaster Interim Fellowship Director
Phone: (415) 487-5034 Fax: (415) 552-0194

University of Cincinnati/Cincinnati Fire Department: Fellowship in Emergency Medical Services
Special Operations Institute The EMS Division has maintained a robust Institute focusing on medical support of field Special Operations. The Institute has five areas of focus: Mass Casualty, Mass Gathering Medicine, Wilderness Medicine, Tactical Medicine, and Dignitary Protection. The EMS Division is heavily involved in the College of Medicine medical student curriculum. Each first year student is trained as a First Responder to prepare for general medical emergencies in the public and clinical settings. Third-year students receive training in emergency preparedness. Up to two Fellows are supported each year.

Applications are accepted on a rolling basis, however successful applicants are generally interviewed in the Fall. The Fellowship is designed for a single year of training. An optional second year is available with completion of a Masters in Public Health Leadership, Management and Policy, or Masters in Public Health-Health Education/Health Promotion.


For more information contact:
Dr. Jason McMullan
evail: Jason.McMullan@uc.edu